scholarly journals BIRC3 is a differentially expressed gene in the tumors of breast cancer patients treated with trastuzumab.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Differentially Expressed Gene ◽  
Growth Factor Receptor ◽  
Metastatic Breast ◽  
The United States ◽  
Differentially Expressed ◽  
Breast Cancer Patients ◽  
Primary Tumors ◽  
Unbiased Manner ◽  
Epidermal Growth

Trastuzumab (Herceptin) is a monoclonal antibody targeting the extracellular domain of the human epidermal growth factor receptor 2 (HER2) (1) utilized for the treatment of adjuvant and metastatic breast cancer (2) in the United States and worldwide. We mined published microarray and gene expression data (3, 4) to discover in an unbiased manner the most striking transcriptional features of trastuzumab treatment. We found that BIRC3 was among the the genes most differentially expressed in the primary tumors of patients treated with trastuzumab. BIRC3, a molecule with the capacity to promote the survival of cancer cells (5), was expressed at significantly higher levels in the primary tumors of patients treated with trastuzumab as compared to that of patients not treated with trastuzumab.

scholarly journals The tumors of breast cancer patients treated with trastuzumab express significantly increased quantities of CD34.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Differentially Expressed Gene ◽  
Growth Factor Receptor ◽  
Metastatic Breast ◽  
The United States ◽  
Normal Breast ◽  
Breast Cancer Patients ◽  
Primary Tumors ◽  
Unbiased Manner ◽  
Epidermal Growth

Trastuzumab (Herceptin) is a monoclonal antibody targeting the extracellular domain of the human epidermal growth factor receptor 2 (HER2) (1) utilized for the treatment of adjuvant and metastatic breast cancer (2) in the United States and worldwide. We mined published and public microarray and gene expression data (3, 4) to discover in an unbiased manner the most striking transcriptional features of trastuzumab treatment. We found that the primary tumors of patients treated with trastuzumab express significantly higher levels of CD34 than do those of patients not treated with trastuzumab. CD34 is a differentially expressed gene that distinguishes breast cancer from the normal breast (5), and these data demonstrate that trastuzumab enhances, not reverses, a marker of the breast tumor.

scholarly journals NEUROD4 is differentially expressed in the tumors of breast cancer patients treated with trastuzumab.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Messenger Rna ◽  
Growth Factor Receptor ◽  
Metastatic Breast ◽  
The United States ◽  
Differentially Expressed ◽  
Breast Cancer Patients ◽  
Primary Tumors ◽  
Unbiased Manner

Trastuzumab (Herceptin) is a monoclonal antibody targeting the extracellular domain of the human epidermal growth factor receptor 2 (HER2) (1) utilized for the treatment of adjuvant and metastatic breast cancer (2) in the United States and worldwide. We mined published microarray and gene expression data (3, 4) to discover in an unbiased manner the most significant transcriptional changes associated with trastuzumab treatment. We identified NEUROD4 among the genes most differentially expressed in the primary tumors of patients with breast cancer treated with trastuzumab. The primary tumors of breast cancer patients treated with trastuzumab expressed higher levels of NEUROD4 messenger RNA than did patients not treated with trastuzumab, and a single administration of trastuzumab was sufficient to result in differential expression of NEUROD4 in primary tumors of the breast, demonstrating increased expression of a transcription factor with neurogenic potential (5, 6) as a direct transcriptional consequence of treatment with trastuzumab.

scholarly journals BIRC8 is differentially expressed in the tumors of breast cancer patients treated with trastuzumab.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Growth Factor Receptor ◽  
Metastatic Breast ◽  
The United States ◽  
Differentially Expressed ◽  
Direct Result ◽  
Breast Cancer Patients ◽  
Primary Tumors ◽  
Unbiased Manner ◽  
Transcriptional Changes

Trastuzumab (Herceptin) is a monoclonal antibody targeting the extracellular domain of the human epidermal growth factor receptor 2 (HER2) (1) utilized for the treatment of adjuvant and metastatic breast cancer (2) in the United States and worldwide. We mined published microarray data (3, 4) to discover in an unbiased manner the most significant transcriptional changes associated with trastuzumab treatment. We identified the baculoviral IAP repeat-containing 8 (encoded by BIRC8) as among the genes most differentially expressed in the primary tumors of patients with breast cancer treated with trastuzumab. A single dose of trastuzumab was sufficient to result in differential expression of BIRC8 in the primary tumors of patients with breast cancer, suggesting that transcriptional induction of BIRC8 is a direct result of trastuzumab administration.

scholarly journals The slit guidance ligand 1, SLIT1, is differentially expressed in the tumors of breast cancer patients treated with trastuzumab.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Messenger Rna ◽  
Growth Factor Receptor ◽  
Metastatic Breast ◽  
The United States ◽  
Differentially Expressed ◽  
Breast Cancer Patients ◽  
Primary Tumors ◽  
Unbiased Manner

Trastuzumab (Herceptin) is a monoclonal antibody targeting the extracellular domain of the human epidermal growth factor receptor 2 (HER2) (1) utilized for the treatment of adjuvant and metastatic breast cancer (2) in the United States and worldwide. We mined published microarray and gene expression data (3, 4) to discover in an unbiased manner the most significant transcriptional changes associated with trastuzumab treatment. We identified the slit guidance ligand 1, encoded by SLIT1, as among the genes most differentially expressed in the primary tumors of patients with breast cancer treated with trastuzumab. The primary tumors of breast cancer patients treated with trastuzumab expressed higher levels of SLIT1 messenger RNA than did patients not treated with trastuzumab, and a single administration of trastuzumab was sufficient to result in differential expression of SLIT1 in primary tumors of the breast, demonstrating increased expression of a ligand involved in guidance of axon migration in the central nervous system (5-9) as a direct transcriptional consequence of treatment with trastuzumab.

scholarly journals Collagen β(1-O) galactosyltransferase 2 (COLGAT2) is differentially expressed in the tumors of breast cancer patients treated with trastuzumab.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Messenger Rna ◽  
Growth Factor Receptor ◽  
Metastatic Breast ◽  
The United States ◽  
Differentially Expressed ◽  
Breast Cancer Patients ◽  
Primary Tumors ◽  
Unbiased Manner

Trastuzumab (Herceptin) is a monoclonal antibody targeting the extracellular domain of the human epidermal growth factor receptor 2 (HER2) (1) utilized for the treatment of adjuvant and metastatic breast cancer (2) in the United States and worldwide. We mined published microarray data (3, 4) to discover in an unbiased manner the most significant transcriptional changes associated with trastuzumab treatment. We identified the collagen β(1-O) galactosyltransferase 2, COLGALT2, as among the genes most differentially expressed in the primary tumors of patients with breast cancer treated with trastuzumab. The primary tumors of breast cancer patients treated with trastuzumab expressed higher levels of COLGALT2 messenger RNA than did patients not treated with trastuzumab, demonstrating increased expression of an enzyme involved in collagen glycosylation and associated with metastasis and proliferation in osteosarcoma (5) as a transcriptional consequence of treatment with trastuzumab.

scholarly journals The EphB4 receptor is differentially expressed in the tumors of breast cancer patients treated with trastuzumab.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Messenger Rna ◽  
Growth Factor Receptor ◽  
Metastatic Breast ◽  
The United States ◽  
Differentially Expressed ◽  
Breast Cancer Patients ◽  
Primary Tumors ◽  
Unbiased Manner

Trastuzumab (Herceptin) is a monoclonal antibody targeting the extracellular domain of the human epidermal growth factor receptor 2 (HER2) (1) utilized for the treatment of adjuvant and metastatic breast cancer (2) in the United States and worldwide. We mined published microarray and gene expression data (3, 4) to discover in an unbiased manner the most significant transcriptional changes associated with trastuzumab treatment. We identified EphB4 as among the genes most differentially expressed in the primary tumors of patients with breast cancer treated with trastuzumab. The primary tumors of breast cancer patients treated with trastuzumab expressed lower levels of EphB4 messenger RNA than did patients not treated with trastuzumab, and a single administration of trastuzumab was sufficient to result in differential expression of EphB4 in primary tumors of the breast, demonstrating decreased expression of a receptor tyrosine kinase that can impair tumorigenicity of breast cancer cells (5) as a direct transcriptional result of treatment with trastuzumab.

scholarly journals Cdc25C is differentially expressed in the tumors of breast cancer patients treated with trastuzumab.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Messenger Rna ◽  
Growth Factor Receptor ◽  
Metastatic Breast ◽  
The United States ◽  
Differentially Expressed ◽  
Breast Cancer Patients ◽  
Primary Tumors ◽  
Unbiased Manner

Trastuzumab (Herceptin) is a monoclonal antibody targeting the extracellular domain of the human epidermal growth factor receptor 2 (HER2) (1) utilized for the treatment of adjuvant and metastatic breast cancer (2) in the United States and worldwide. We mined published microarray and gene expression data (3, 4) to discover in an unbiased manner the most striking transcriptional features of trastuzumab treatment. We identified the activator of the maturation-promoting factor, CDC25C (5-12) as among the genes most differentially expressed in the primary tumors of patients with breast cancer treated with trastuzumab. The primary tumors of breast cancer patients treated with trastuzumab expressed higher levels of CDC25C messenger RNA than did patients not treated with trastuzumab, and a single administration of trastuzumab was sufficient to result in differential expression of CDC25C in primary tumors of the breast, demonstrating that a critical component of the cellular machinery that facilitates progression of cells through mitosis (5-12) is likely transcriptionally induced in primary tumors of the breast by trastuzumab.

scholarly journals The interleukin-23 receptor and a subunit for the IL-23 cytokine, IL-23A, are differentially expressed in the tumors of breast cancer patients treated with trastuzumab.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Messenger Rna ◽  
Growth Factor Receptor ◽  
Metastatic Breast ◽  
The United States ◽  
Differentially Expressed ◽  
Breast Cancer Patients ◽  
Primary Tumors ◽  
Unbiased Manner ◽  
Interleukin 23

Trastuzumab (Herceptin) is a monoclonal antibody targeting the extracellular domain of the human epidermal growth factor receptor 2 (HER2) (1) utilized for the treatment of adjuvant and metastatic breast cancer (2) in the United States and worldwide. We mined published and public microarray data (3-6) to discover in an unbiased manner the most significant transcriptional changes associated with trastuzumab treatment. We identified the receptor for interleukin-23, IL23R, among the genes most differentially expressed in the primary tumors of patients with breast cancer treated with trastuzumab (3, 4). We also found that the alpha subunit of the IL-23 cytokine, IL23A, was among the genes whose expression changed most significantly in the primary tumors of patients treated with trastuzumab (5, 6). IL23R messenger RNA was expressed at significantly higher levels in the primary tumors of patients treated with trastuzumab than patients not treated with trastuzumab, demonstrating increased expression of the receptor for a cytokine that has been described to promote tumor growth (7) as a transcriptional consequence associated with treatment with trastuzumab.

scholarly journals BMPR1B is differentially expressed in the tumors of breast cancer patients treated with trastuzumab.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Messenger Rna ◽  
Growth Factor Receptor ◽  
Metastatic Breast ◽  
The United States ◽  
Differentially Expressed ◽  
Breast Cancer Patients ◽  
Primary Tumors ◽  
Unbiased Manner

Trastuzumab (Herceptin) is a monoclonal antibody targeting the extracellular domain of the human epidermal growth factor receptor 2 (HER2) (1) utilized for the treatment of adjuvant and metastatic breast cancer (2) in the United States and worldwide. We mined published microarray and gene expression data (3, 4) to discover in an unbiased manner the most significant transcriptional changes associated with trastuzumab treatment. We identified BMPR1B among the genes most differentially expressed in the primary tumors of patients with breast cancer treated with trastuzumab. The primary tumors of breast cancer patients treated with trastuzumab expressed higher levels of BMPR1B messenger RNA than did patients not treated with trastuzumab, and a single administration of trastuzumab was sufficient to result in differential expression of BMPR1B in primary tumors of the breast, demonstrating increased expression of a receptor subunit for a bone morphogenetic protein that is important for development of the ventral retina and optic nerve (5) as a direct transcriptional consequence of treatment with trastuzumab.

scholarly journals The recombination activating gene 2, RAG2, is differentially expressed in the tumors of breast cancer patients treated with trastuzumab.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Growth Factor Receptor ◽  
Metastatic Breast ◽  
The United States ◽  
Differentially Expressed ◽  
Breast Cancer Patients ◽  
Specific Expression ◽  
Primary Tumors ◽  
Unbiased Manner ◽  
Recombination Activating Gene

Trastuzumab (Herceptin) is a monoclonal antibody targeting the extracellular domain of the human epidermal growth factor receptor 2 (HER2) (1) utilized for the treatment of adjuvant and metastatic breast cancer (2) in the United States and worldwide. We mined published microarray data (3, 4) to discover in an unbiased manner the most significant transcriptional changes associated with trastuzumab treatment. We identified the recombination activating gene, RAG2, as among those most differentially expressed in the primary tumors of patients with breast cancer treated with trastuzumab. A single administration of trastuzumab was sufficient to transcriptionally activate RAG2 in primary tumors of the breast, demonstrating increased expression of a molecule thought to possess cell type-specific expression in B-lymphocytes as a direct transcriptional consequence of treatment with trastuzumab.

Sign in / Sign up

Export Citation Format

Share Document